Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin-Reference-Cited by-同舟云学术

Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin

Published:2012-05-15 Issue:4 Volume:13 Page:335-341
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Iacobucci I,Lonetti A,Candoni A,Sazzini M,Papayannidis C,Formica S,Ottaviani E,Ferrari A,Michelutti A,Simeone E,Astolfi A,Abbenante M C,Parisi S,Cattina F,Malagola M,Russo D,Damiani D,Gherlinzoni F,Gottardi M,Baccarani M,Fanin R,Martinelli G

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj201213.pdf

Reference33 articles.

1. Deeken J . The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Ther 2009; 11: 260–268.

2. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193–202.

3. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–1431.

4. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I . Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008; 9: 415–422.

5. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363–375.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships;Frontiers in Pharmacology;2024-03-22

2. Pharmacogenomics and Cancer Treatment;Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy;2023

3. Next-Generation Sequencing and Bioinformatics-Based Protocol for the Full-Length CYP2E1 Gene Polymorphism Analysis;Pharmacogenomics and Personalized Medicine;2022-11

4. Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia;Journal of Personalized Medicine;2022-09-29

5. Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response;Pharmaceuticals;2022-08-11